Ariba, Inc. (Nasdaq:ARBA), the leading spend management solutions
provider, today announced that Pfizer Switzerland is expanding its use
of Ariba solutions. Pfizer Switzerland has been using a range of Ariba
solutions to streamline procurement and lower costs since 2004. To
extend and accelerate the savings and efficiencies that it has
achieved to date, Pfizer Switzerland is broadening its portfolio
beyond procurement to include solutions aimed at enhancing its
sourcing process.
"A key part of our success in supply management has been the use
of Ariba´s spend management solutions, which allow us to drive
critical initiatives to manage costs and deliver bottom line results,"
said Denise Gerber, Head of Sourcing & Supply Chain Management at
Pfizer, Switzerland.
An early adopter of spend management solutions, Pfizer Switzerland
initially sought to lower its costs of doing business. Leveraging
Ariba(R) Buyer(TM), the company has achieved this goal by streamlining
the procurement of simple and complex categories from orders through
invoices and payment. In adding Ariba Sourcing(TM), Pfizer Switzerland
was able to shorten tender processes. Even complex categories of spend
such as sales and marketing and professional services can be handled
through this module.
"Successful sourcing requires more than just technology," Gerber
added. "With Ariba´s deep category expertise and market knowledge,
which is a perfect match to our sourcing project teams, we have access
to all of the tools we need to advance our initiatives and accelerate
the results that they deliver."
"Pfizer Switzerland was among the first companies to embrace spend
management and has successfully leveraged technology-based solutions
to simplify procurement and lower costs," said Mike Arenth, Vice
President and General Manager, EMEA, Ariba.
About Pfizer Schweiz AG
Pfizer Schweiz AG is the Swiss subsidiary of Pfizer Inc., the
world´s largest research-based pharmaceutical company. The company
employs approximately 220 people in Switzerland and sells more than
100 drugs. The main therapeutic classes are cardiovascular disease,
diabetes, pulmonary disease, pain, urology, eye disease, nervous
disorders, infectiology (including HIV) and oncology. The company also
offers a wide range of drugs for livestock and pets. Pfizer has been
registered in Switzerland since 1959 and is one of the most important
pharmaceutical companies in the country, with sales of more than 300
million CHF, hence Pfizer´s commitment to the base in Switzerland.
About Ariba, Inc.
Ariba, Inc. is the leading provider of Spend Management solutions
to help companies realize rapid and sustainable bottom line results.
Successful companies around the world in every industry use Ariba
Spend Management(TM) software and services. Ariba can be contacted in
the U.S. at 1.650.390.1000 or at www.ariba.com.
Copyright (C) 1996 - 2008 Ariba, Inc.
Ariba, the Ariba logo, AribaLIVE and SupplyWatch are registered
trademarks of Ariba, Inc. Ariba Spend Management, Ariba Spend
Management. Find it. Get it. Keep it., Ariba. This is Spend
Management, Ariba Solutions Delivery, Ariba Analysis, Ariba Buyer,
Ariba Category Management, Ariba Category Procurement, Ariba Contract
Compliance, Ariba Contracts, Ariba Contract Management, Ariba Contract
Workbench, Ariba Data Enrichment, Ariba eForms, Ariba Electronic
Invoice Presentment and Payment, Ariba Invoice, Ariba Sourcing, Ariba
Spend Visibility, Ariba Travel and Expense, Ariba Procure-to-Pay,
Ariba Workforce, Ariba Supplier Network, Ariba Supplier Connectivity,
Ariba Supplier Performance Management, Ariba PunchOut, Ariba
QuickSource, PO-Flip, Ariba Settlement, Ariba Spend Management
Knowledge Base, Ariba Ready, Ariba Supply Lines, Ariba Supply Manager,
Ariba LIVE and It´s Time for Spend Management are trademarks or
service marks of Ariba, Inc. All other trademarks are property of
their respective owners.
Ariba Safe Harbor
Safe Harbor Statement under the Private Securities Litigation
Reform Act 1995: Information and announcements in this release involve
Ariba´s expectations, beliefs, hopes, plans, intentions or strategies
regarding the future and are forward-looking statements that involve
risks and uncertainties. All forward-looking statements included in
this release are based upon information available to Ariba as of the
date of the release, and we assume no obligation to update any such
forward-looking statements. These statements are not guarantees of
future performance and actual results could differ materially from our
current expectations. Factors that could cause or contribute to
Ariba´s operating and financial results to differ materially from
current expectations include, but are not limited to: delays in
development or shipment of new versions of Ariba´s products and
services; lack of market acceptance of Ariba´s existing or future
products or services; inability to continue to develop competitive new
products and services on a timely basis; introduction of new products
or services by major competitors; the ability to attract and retain
qualified employees; difficulties in assimilating acquired companies;
long and unpredictable sales cycles and the deferrals of anticipated
orders; declining economic conditions; inability to control costs;
changes in the company´s pricing or compensation policies; significant
fluctuations in our stock price; the outcome of and costs associated
with pending or potential future regulatory or legal proceedings; the
impact of our acquisitions, including the disruption or loss of
customer, business partner, supplier or employee relationships; and
the level of costs and expenses incurred by Ariba as a result of such
transactions. Factors and risks associated with its business,
including a number of the factors and risks described above, are
discussed in Ariba´s Form 10-Q filed with the SEC on February 6, 2008.
